Intrahepatic Cholangiocarcinoma Clinical Trials
Here are the 6 most popular medical studies for intrahepatic cholangiocarcinoma
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Kinase Inhibitor
ICP-192 for Solid Tumors
This trial is testing a new cancer drug, ICP-192, on patients with advanced solid tumors and FGFR gene alterations. The trial has two parts, with the first part testing different doses of the drug to see what is safe and effective, and the second part expanding the study to more patients.
FAPi PET/CT Imaging for Cancer
This trial is looking at a new way to image cancer using a tracer called 68Ga-FAPi-46. The tracer is taken up by some cancers, and can be seen with PET imaging. This may provide additional information about various cancers in the future.
Popular filter options for intrahepatic cholangiocarcinoma trials
Bile Duct Cancer Clinical Trials
View 60 Bile Duct Cancer medical studies.
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial is testing a new cancer treatment for people with biliary tract cancer. The treatment involves a non-myeloablative lymphodepleting preparative regimen, infusion of autologous TIL, and high-dose aldesleukin.
Chemotherapy
Chemotherapy Delivery System for Colorectal and Bile Duct Cancers
This trial is testing whether a Medtronic pump and Codman catheter device is a safe alternative to the C3000 Codman pump for delivering chemotherapy to patients with metastatic colorectal cancer or cholangiocarcinoma.
EBD Cancer Clinical Trials
View 58 EBD Cancer medical studies.
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial is testing a new cancer treatment for people with biliary tract cancer. The treatment involves a non-myeloablative lymphodepleting preparative regimen, infusion of autologous TIL, and high-dose aldesleukin.
Chemotherapy
Chemotherapy Delivery System for Colorectal and Bile Duct Cancers
This trial is testing whether a Medtronic pump and Codman catheter device is a safe alternative to the C3000 Codman pump for delivering chemotherapy to patients with metastatic colorectal cancer or cholangiocarcinoma.
FGFR2 Positive Clinical Trials
View 9 FGFR2 positive medical studies.
Tyrosine Kinase Inhibitor
Pemigatinib +1 More for Bile Duct Cancer
This trial is testing if a combination of two drugs, Afatinib and Pemigatinib, is safe and effective for treating certain types of advanced solid tumors with specific genetic mutations. The study
Kinase Inhibitor
Pemigatinib vs Chemotherapy for Bile Duct Cancer
This trial will compare the effectiveness of pemigatinib versus gemcitabine plus cisplatin chemotherapy as first-line treatment for people with cholangiocarcinoma that cannot be removed by surgery or has spread to other parts of the body.
IDH Positive Clinical Trials
View 6 IDH positive medical studies.
PARP Inhibitor
Olaparib for Advanced Cancer
This trial will study how well olaparib works in treating patients with certain types of cancer that have spread and usually cannot be controlled with treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
IDH1 Inhibitor
Chemotherapy + Targeted Therapy for Bile Duct Cancer
This trial is testing the side effects and best dose of two chemotherapy drugs, gemcitabine and cisplatin, when given with either of two targeted drugs, ivosidenib or pemigatinib, in treating patients with cholangiocarcinoma that cannot be removed with surgery or has spread to other places in the body.
Checkpoint Inhibitor
Ivosidenib + Immunotherapy for Bile Duct Cancer
This trial tests a drug combo to treat cholangiocarcinoma. Safety and effectiveness of the combo will be evaluated. Treatment continues until toxicity, progression, or other criteria are met.
Phase 3 Intrahepatic Cholangiocarcinoma Clinical Trials
View 98 phase 3 intrahepatic cholangiocarcinoma medical studies.
Kinase Inhibitor
Pemigatinib vs Chemotherapy for Bile Duct Cancer
This trial will compare the effectiveness of pemigatinib versus gemcitabine plus cisplatin chemotherapy as first-line treatment for people with cholangiocarcinoma that cannot be removed by surgery or has spread to other parts of the body.
Intrahepatic Cholangiocarcinoma Clinical Trials With No Placebo
View 98 intrahepatic cholangiocarcinoma medical studies that do not have a placebo group.
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial is testing a new cancer treatment for people with biliary tract cancer. The treatment involves a non-myeloablative lymphodepleting preparative regimen, infusion of autologous TIL, and high-dose aldesleukin.
Chemotherapy
Chemotherapy Delivery System for Colorectal and Bile Duct Cancers
This trial is testing whether a Medtronic pump and Codman catheter device is a safe alternative to the C3000 Codman pump for delivering chemotherapy to patients with metastatic colorectal cancer or cholangiocarcinoma.
View More Intrahepatic Cholangiocarcinoma Trials
See another 70 medical studies focused on intrahepatic cholangiocarcinoma.
Frequently Asked Questions
Introduction to intrahepatic cholangiocarcinoma
What are the top hospitals conducting intrahepatic cholangiocarcinoma research?
Intrahepatic cholangiocarcinoma, a rare and aggressive form of liver cancer, has spurred renowned hospitals across the United States to conduct groundbreaking clinical trials in search of effective treatments. Memorial Sloan Kettering Cancer Center in New york leads the charge with 13 active trials dedicated to this condition and a cumulative total of 25 trials since their first recorded exploration in 2000. Meanwhile, Massachusetts General Hospital in Boston follows closely behind with nine ongoing intrahepatic cholangiocarcinoma trials and an impressive history of 19 previous studies dating back to their inaugural trial in 2006.
The University of Texas MD Anderson Cancer Center, located in Houston, is also playing a significant role by conducting eight active clinical trials for intrahepatic cholangiocarcinoma. Their commitment to research began more recently with their first recorded trial occurring just seven years ago in 2014. Additionally, another institution within the MD Anderson network joins the fight against this challenging disease as they too have conducted eight active clinical tests alongside fifteen past investigations since initiating their pioneering study on intrahepatic cholangiocarcinoma starting from 2011.
Lastly but not leastly; yet another branch from M D Anderson Cancer Center based out at Houston has made its own mark by actively spearheading six current explorations while carrying out sixteen former efforts after taking initiative commencing only around decade ago,in year2014to broaden horizons for such patients battling against Intraheptic Chlangocarcoma
These esteemed hospitals are at the forefront of cutting-edge research into finding better treatment options for those affected by intrahepatic cholangiocarcinoma. With each new trial and every breakthrough discovery, we move one step closer towards improving outcomes and offering hope to individuals facing this formidable disease.
Which are the best cities for intrahepatic cholangiocarcinoma clinical trials?
When it comes to clinical trials for intrahepatic cholangiocarcinoma, several cities in the United States are leading the way. Houston, Texas stands out with 37 active trials, investigating treatments like NGM831 and RLY-4008. New york City and Boston tie at 32 active trials each, exploring options such as gavo-cel and Cobimetinib respectively. Los Angeles, California follows closely behind with 26 ongoing studies focused on Nivolumab and pembrolizumab among others. While Anchorage, Alaska also has 26 active trials underway examining treatments like Arm B (pevonedistat, paclitaxel, carboplatin) and Cisplatin. These cities offer individuals diagnosed with intrahepatic cholangiocarcinoma access to cutting-edge clinical research that may lead to better treatment outcomes and improved quality of life.
Which are the top treatments for intrahepatic cholangiocarcinoma being explored in clinical trials?
Clinical trials are exploring various treatments to combat intrahepatic cholangiocarcinoma, a challenging form of cancer. Among the leading contenders are gemcitabine, having 5 active and 51 all-time trials since its introduction in 2002; durvalumab with 2 ongoing and a total of 16 clinical trials for this specific type of cancer since it first appeared in 2016; tivozanib, a newcomer with two current studies and two overall trials dedicated to intrahepatic cholangiocarcinoma starting from its listing in 2021; and olaparib, also involved in two active trials out of five cumulative investigations focused on this disease since being listed as a potential treatment option in 2019. These advancements offer hope for patients battling intrahepatic cholangiocarcinoma.
What are the most recent clinical trials for intrahepatic cholangiocarcinoma?
Exciting advancements are underway in the field of intrahepatic cholangiocarcinoma, with recent clinical trials offering promising prospects for patients. One notable trial is evaluating the efficacy of Tinengotinib 8 mg QD as a potential treatment option in Phase 3. Additionally, Phase 2 trials are exploring various approaches such as Arm A and Gemcitabine + Cisplatin + Durvalumab + Yttrium-90 Selective Internal Radiation Therapy to address this challenging cancer type. These studies aim to uncover new strategies and therapeutic combinations that may significantly improve outcomes for individuals battling intrahepatic cholangiocarcinoma.
What intrahepatic cholangiocarcinoma clinical trials were recently completed?
Several clinical trials exploring innovative treatments for intrahepatic cholangiocarcinoma have recently concluded, signifying important progress in the field. In August 2020, Celldex Therapeutics completed a trial investigating CDX-527's potential as a targeted therapy. Similarly, the National Cancer Institute wrapped up their study on MVT-5873 in November 2019. Mayo Clinic also contributed to this research by completing a trial on Trifluridine and Tipiracil Hydrochloride in October 2019. These advancements underscore the commitment of researchers to finding new approaches to combatting intrahepatic cholangiocarcinoma and bring hope to patients facing this challenging disease.